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Objective: We performed a cost–utility analysis to assess the cost-effectiveness of a 
chemotherapy sequence including a combination of polyethylene glycolated liposomal 
doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in 
women with platinum-sensitive ovarian cancer.
Methods: A Markov model was constructed with a 10-year time horizon. The treatment 
sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before 
death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The 
model consisted of four health states: responsive, progressive, clinical remission, and death. At 
any given time, a patient may have remained on a current therapy or made a transition to the 
next therapy or death. Median time to progressions and overall survivals data were obtained 
through a systematic literature review and were pooled using a meta-analytical approach. If 
unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted 
to transition probabilities using an appropriate formula. Direct costs included drug-acquisition 
costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy 
evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were 
transportation expenses. Utilities were also derived from the literature. Costs and utilities were 
discounted at an annual rate of 5% per cycle.
Results: PLD/carboplatin combination as the second line in the sequence is more effective and 
costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-
adjusted life years. This result was robust in a deterministic sensitivity analysis except when 
median time to progression of second-line therapies and administration cost of PLD/carboplatin 
per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin 
combination was 49.4% at a willingness to pay $20,000.
Conclusion: A PLD/carboplatin combination is an economically valuable option as second-line 
chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea.
Keywords: cost, utility, Markov modeling, ovarian cancer, chemotherapy
Introduction
Ovarian cancer is the third-commonest type of cancer of the female reproductive 
system, after breast cancer and cervical cancer in Korea. It has a high mortality and a 
low 5-year survival rate (around 30%).1
Epithelial ovarian cancer is often diagnosed at advanced stages or misdiagnosed 
as other diseases, because patients don’t show specific symptoms until the illness 
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progresses to advanced stages, at which point the response 
to surgery and chemotherapy is poor.2,3
The European Society of Medical Oncology4 and 
Korean practice guidelines for ovarian cancer5 recommend 
performing a primary optimal debulking surgery first, before 
the start of chemotherapy. Taxane/platinum (especially 
carboplatin) is recommended as a first-line chemotherapy, 
with dosing frequency varying depending on the stage of the 
cancer. In the case of recurrence after first-line chemotherapy, 
a different strategy should be applied depending on whether 
the recurrence occurs within 6 months since the first-line 
therapy. Patients who relapse within 6 months, ie, “platinum-
resistant” patients change to another chemotherapy option, 
while patients who relapse after 6 months since the first-
line therapy, ie, “platinum-sensitive” patients, receive the 
platinum-based therapy once more.5,6
Korean practice guidelines for ovarian cancer recommend 
topotecan, gemcitabine, vinorelbine, and liposomal 
doxorubicin as the second-line therapy for platinum-resistant 
patients, and topotecan is used dominantly among these 
drugs. For platinum-sensitive patients who relapse after 
6 months, paclitaxel/carboplatin, the same chemotherapy 
as the first-line therapy, is administered as the second-line 
therapy.
The active ingredient of polyethylene glycolated 
liposomal doxorubicin (PLD) is PLD hydrochloride, which 
passes through the target cell and suppresses ligation of a 
nucleotide strand, DNA replication, and ultimately protein 
synthesis. It results in an altered kinetic profile, extending 
the half-life to 74 hours. In addition, it increases the efficacy 
and decreases many of the side effects by improving the 
specificity of delivery to the tumors, reducing absorption by 
normal tissues, compared to doxorubicin.7
PLD can be used for both platinum-resistant and 
platinum-sensitive patients.8 It was proven in a head-to-
head randomized controlled trial (RCT) that PLD was equal 
in efficacy and superior in safety profile to topotecan in 
platinum-resistant patients.9 In addition, PLD/carboplatin 
also showed superior efficacy as the second-line therapy 
in platinum-sensitive patients, extending progression-free 
survival (PFS) 2 months longer than paclitaxel/carboplatin, 
which was statistically significant in a head-to-head RCT 
(hazard ratio 0.821, 95% confidence interval 0.72–0.94; 
P = 0.005) (CALYPSO study).10
Based on the clinical trial that proved parity of clinical 
efficacy of PLD with topotecan, cost-minimization analyses 
for platinum-resistant patients have been performed in many 
countries, such as Spain, Italy, the US, and the UK, showing 
that PLD can save costs compared to topotecan.11,12 To date, 
however, there has been no study that has evaluated the 
cost-effectiveness of PLD for platinum-sensitive patients. 
Thus, we developed a sequence model for an economic 
evaluation of PLD/carboplatin as second-line therapy, in 
which the treatment protocol of ovarian cancer in the real 
world was reflected, and explored the long-term clinical and 
economic impact of PLD/carboplatin in platinum-sensitive 
recurrent ovarian cancer patients. This study is the first, 
both internationally and domestically, to evaluate the cost-
effectiveness of treatment sequences in women with recurrent 
ovarian cancer.13
Methods
Model structure
A Markov cohort simulation model was developed using 
a Microsoft Excel spreadsheet to estimate the costs and 
health outcomes in terms of life years gained (LYGs) and 
quality adjusted life years (QALYs) for the full range of 
relevant treatment strategies. The model consisted of four 
health states, ie, response and progress to each separate line 
of therapy, clinical remission, and death, so that the two 
cohorts of identical patients receiving a series of six different 
chemotherapies and best supportive care (BSC) could be 
compared (Figure 1, Table 1). BSC means palliative therapy 
without active treatment, due to treatment toxicity, patient 
frailty, or lack of benefit.
There is a need to define a confoundable term beforehand. 
Generally, chemotherapy for cancer treatment is administered 
at intervals of 3 or 4 weeks, which is termed a “cycle.” In 
the absence of unacceptable toxicity or disease progression, 
patients are supposed to receive a total of six cycles of 
chemotherapy and then enter the withdrawal period, which 
is considered “clinical remission” in this model (Figure 1). 
On the other hand, the length of time during which a patient 
can move to another health state in the model is also called a 
cycle in the field of modeling of economic analysis. This cycle 
BSC
Progress Progress
2nd tx 3rd~6th tx
Respond Respond
RemissionRemission
Death
Figure 1 Structure of Markov model.  
Notes: The different compartments are mutually exclusive health states. Arrows 
represent allowed transitions between states. “Progress/stable” state is “tunnel” state.
Abbrebiations: tx, treatment; BSC, best supportive care.
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in the model can be confused with the aforementioned cycle 
of chemotherapy administration. Therefore, the latter shall 
be termed “Markov cycle,” while the former shall be termed 
“administration cycle.”
Patients are assumed to receive six lines of chemotherapy 
on average after diagnosis of ovarian cancer until death, 
according to an expert group composed of five clinical 
gynecologists in South Korea. So the model reflected 
this. Cohort A and B included the combination therapy of 
PLD/carboplatin and paclitaxel/carboplatin, respectively, 
as the second-line therapy in the treatment sequence. The 
third- to sixth-line therapies were common to the two cohorts 
(Table 1).
Patients remained on the same therapy for six 
administration cycles (18 weeks), at maximum, if they 
responded to the drug. If patients did not progress or show 
any serious side effects after six administration cycles, they 
would enter a clinical remission state, withdrawing from the 
drug. If the disease progressed during the treatment, patients 
would transit to the next line of therapy. “Progress” is a 
tunnel state. In other words, patients have to pass through the 
“progress” state to enter the subsequent line of therapy and 
cannot revert to an earlier line of therapy. Death could occur 
at any point during the Markov cycle (Figure 1).
The overall clinical validity of the model was confirmed 
by an expert group. Information on the chemotherapies 
most commonly used from the third to the sixth line in the 
treatment sequence of ovarian cancer, average median time 
to progression (TTP) of BSC, overall protocols related with 
drug administration, and the treatment of adverse events due 
to each therapy was also obtained from them.
The length of the Markov cycle defines the period of 
transition between the health states within the Markov 
model and depends on the characteristics of the disease. The 
length of the model cycle in this analysis was determined as 
9 weeks for the following reason. Most chemotherapies are 
administered at 3-week intervals (one administration cycle). 
After three administration cycles, ie, 9 weeks, a series of tests 
for evaluating responsiveness to chemotherapy administered 
are performed, and according to the test result, it is determined 
whether the patient will move to the next line of therapy or stay 
on the current one. A cycle length of 9 weeks was determined 
to reflect this clinical practice in the real world.
Transition probabilities to the next line of therapies and 
death were drawn from the treatment-specific median TTP or 
PFS and over survival (OS) data obtained from clinical trials.
The time horizon should be enough to observe the 
long-term efficacy of intervention. Because the ultimate aim 
of an anticancer drug is to prolong patients’ lives, the time 
horizon was set as 10 years in this analysis, at which 99% 
of the cohorts died.
Assumptions
•	 Patients received six lines of chemotherapy, on average, 
from the diagnosis of ovarian cancer until death.
•	 All patients experiencing disease progression received 
the next line of chemotherapy with no other treatment 
options, such as radiotherapy.
•	 All patients experiencing disease progression on BSC 
died.
•	 Chemotherapies were performed on the basis of 
ambulatory visits.
•	 Cisplatin and carboplatin as a sixth-line therapy were 
used on a fifty–fifty basis among patients.
•	 PLD/carboplatin is supposed to be administered at 4-week 
intervals, while the others are administered at 3-week 
intervals, according to the approved drug indication. 
However, it was assumed that all chemotherapies were 
administered at 3-week intervals, which is the assumption 
conservative to PLD.
•	 If patients showed progression to the sixth line of therapy, 
they would receive just BSC without any medical 
treatment. Patients on BSC used mainly in-home service 
and hospice service. Hospice service was used only for 
the last week before death.
•	 The model started from the second-line therapy.
Model estimates: transition probability 
distributions
Transition probabilities to the next line of therapy and death 
were calculated from the treatment-specific median TTP and 
OS data, using the equation below.14
Table 1 Treatment sequence for cohort A vs cohort B
Cohort A Cohort B
Chemotherapy PLD/carboplatin 
↓	
Topotecan or belotecan 
↓	
Docetaxel 
↓	
Etoposide 
↓	
Carboplatin or cisplatin
Paclitaxel/carboplatin 
↓	
Topotecan or belotecan 
↓	
Docetaxel 
↓	
Etoposide 
↓	
Carboplatin or cisplatin
Best supportive 
care
in-home service 
↓	
Hospice service
in-home service 
↓	
Hospice service
Abbreviation: PLD, polyethylene glycolated liposomal doxorubicin.
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For this, RCTs and other experimental studies published 
in English and Korean from January 1990 to January 2012 
were searched using PubMed and the Cochrane database by a 
systematic review. Information where several different terms 
may be used for the same concept, such as ovarian cancer 
and TTP, was retrieved using Medical Subject Headings 
(MeSH). Systematic literature reviews were also included. 
After checking individual RCTs referenced in the systematic 
literature reviews, ones not overlapping with other RCTS in 
our search list were included.
In total, 808 papers were identified. After two reviewers 
independently reviewed the titles and abstracts primarily 
to identify the studies meeting the inclusion/exclusion 
criteria, 641 papers were excluded. Then, the full texts of 
the remaining 108 papers were reviewed, and 18 papers and 
one proceeding remained. All these procedures were cross-
checked between the two reviewers.
Medial TTP and OS data obtained from the literature were 
merged using a weighted average based on the sample size 
(Table 2). Outcomes of the second-line chemotherapies in 
the base-case analysis were extracted from only head-to-head 
RCTs, even though there were other non-head-to-head trials 
meeting inclusion criteria. This was because the second-line 
drugs were the main target of this analysis. Outcomes of 
third-line chemotherapy were extracted from two studies,15, 
fourth-line from one,16 fifth-line from one,17 and sixth-line 
from three.18–20 The median TTP of BSC was obtained from 
opinions of clinical experts.
Model estimates: cost
Since the analysis was carried out from the societal 
perspective, both nonmedical and medical costs associated 
with treatments were included. However, indirect costs, 
such as costs incurred by productivity loss of patient 
and informal caregivers, were excluded, because not 
only there are possibilities such as double-counting and 
overestimation but also there is no agreed methodology 
for measurement.
Direct medical cost includes cost associated with 
drug administration (ie, cost for drug acquisition, 
tests for monitoring adverse events, evaluation of 
responsiveness to chemotherapy, treatment of adverse 
events occurring during each chemotherapy, and service 
for drug administration), BSC, and follow-up tests 
during clinical remission. Cost items not reimbursed 
by insurance couldn’t be identified because of a lack of 
data. Therefore, the mean proportion of cost incurred by 
nonreimbursement items in cancer patients was applied. 
Direct nonmedical costs include round-trip transportation 
costs for every ambulatory visit.
Most of the costs, except for nonreimbursement cost 
and hospice service, were estimated based on microcosting. 
Information concerning the proportion of cost not covered 
by insurance was retrieved from the report by the National 
Health Insurance Corporation (NHIC) in 2009.21 However, 
this did not report ovarian cancer patient-specific data, but 
rather overall cancer patients’ data. Therefore, data of the 
overall cancer patients was put into the model. Hospice 
service cost was from the literature.22 Since PLD has not 
been listed on reimbursement yet, the price of PLD estimated 
by the manufacturer was put into the base-case analysis. 
Acquisition costs of other drugs were obtained from the 
ceiling price paid by insurance.
Cost items and frequencies of service use were 
estimated based on the current domestic and foreign clinical 
practice guidelines, literature, and expert opinions. Fee of 
service for drug administration, tests, and treatments of 
adverse events were drawn from the Korean fee schedule. 
Because the model starts from the second line, the cost of 
Table 2 Clinical parameters of chemotherapies
Line Therapy Median TTP 
(month)
Probability Median OS 
(month)
Probability
2nd PLD/carboplatin 11.30 0.8804 30.70 0.0458
Paclitaxel/carboplatin 9.40 0.8580 33.00 0.0427
3rd Topotecan 6.34 0.7968 18.28 0.0758
4th Docetaxel 4.60 0.7313 13.70 0.0997
5th Etoposide 6.30 0.7957 16.50 0.0836
6th Carboplatin or cisplatin 12.71 0.8929 20.45 0.0680
BSC 4.50 0.7262 4.50 1
Abbreviations: TTP, time to progression; OS, overall survival; PLD, polyethylene glycolated liposomal doxorubicin; BSC, best supportive care.
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initial diagnosis for ovarian cancer was excluded. It was 
assumed that all the chemotherapies were performed on 
ambulatory visits and patients experienced adverse events 
only once since starting each chemotherapy treatment. The 
costs for drug acquisition, administration, and treatment of 
adverse event per Markov cycle (9 weeks) are presented 
in Table 3.
In-home service costs include costs for paracentesis 
and pain management. The costs for hospice service were 
calculated as weighted average with costs by the types of 
hospice facility and proportion of use. The cost for follow-up 
tests during clinical remission and BSC is also presented in 
Table 3.
All costs were converted to 2011 value and expressed 
in both Korean won (￦) and US dollars. An exchange rate 
of ￦1130 to $1 was applied (official exchange rate as of 
March 22, 2012).
Model estimates: utility
The final outcome measures used to evaluate the efficacy 
in this model were LYGs and QALYs. Because there are 
no QALY data of Korean ovarian cancer patients, they 
were drawn from foreign literature searched by systematic 
review, using PubMed CRD23 and the utility registry home 
database of Tufts Medical Center in Boston.24 There was 
only one study in which QALYs appropriate for health 
states defined in this model were surveyed, targeting both 
ovarian cancer patients and the general public.25 Although 
utility values were reported by the adverse-event grades in 
the literature, they could not be used, as it is impossible to 
know the incidence rate of each adverse event by toxicity 
grades from clinical trials. Therefore, the proportion of 
grades 1–2 to 3–4 was assumed to be 50:50. Uncertainty 
surrounding this assumption was investigated in a 
sensitivity analysis.
There is one more thing to note. This study reported two 
results measured by both time trade-off (TTO) and visual 
analog scale (VAS). However, the result measured by TTO 
in this study was somewhat counterintuitive. It was reported 
in this study that QALYs of higher-grade adverse events 
were higher than those of lower-grade adverse events. This 
is presumed to be a mere input error, as it is natural that the 
higher the grade of adverse event, the lower the QALY figure 
will be. However, it does not affect the result, because the 
mean utility of grade 1–2 and 3–4 toxicity was the input in 
our model. Because TTO is a more recommendable method 
considering its reliability and consistency, the result measured 
by TTO was used in the base-case analysis (Table 4).
Results
Base-case analysis
The base-case analysis compares two cohorts composed 
of 1000 recurrent ovarian cancer patients, each receiving 
different treatment sequences, including PLD/carboplatin 
(cohort A) and paclitaxel/carboplatin (cohort B) as the 
second line.
In Figure 2, which shows the number of patients starting 
each line of therapy, fewer patients would eventually receive 
BSC in cohort A than in cohort B. This is because more patients 
exited the model due to death in cohort A than in cohort B.
Table 5 summarizes the expected total costs of two cohorts 
during each separate line of therapy and the difference in the 
Table 3 Cost associated with drug administration and treatment of adverse events in each line of chemotherapy, follow-up test, 
and BSC
Chemotherapy Line of treatment Drug acquisition cost, 
US$ (Korean won)
Cost of drug administration 
per model cycle, US$ 
(Korean won)
Cost for treatment 
of adverse event US$ 
(Korean won)
PLD/carboplatin 2 1025 (1,158,600) 4357 (4,185,052) 94 (106,484)
Paclitaxel/carboplatin 2 656 (740,958) 3053 (2,932,126) 103 (116,326)
Topotecan 3 1743 (1,969,445) 6875 (6,603,593) 199 (225,084)
Docetaxel 4 874 (987,600) 3732 (3,584,956) 211 (239,218)
Etoposide 5 26 (29,088) 720 (691,144) 123 (127,135)
Carboplatin or cisplatin 6 113 (127,651) 1137 (1,092,205) 27 (30,185)
Item Cost, US$ (Korean won)
Cost for follow-up test 99 (111,313)
BSC cost
 in-home service 2498 (2,823,152)
 Hospice cost 1180 (1,333,699)
Notes: Drug acquisition cost includes dilute solution; cost of drug administration comprised of drug-acquisition cost, monitoring tests of adverse events, evaluation tests for 
response to chemotherapy, service for drug administration, remission, and nonreimbursement cost.
Abbreviations: PLD, polyethylene glycolated liposomal doxorubicin; BSC, best supportive care.
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base-case analysis. Net costs per patient are also presented. 
Costs in each line of therapy are higher in cohort B than in 
cohort A, except for the second line of therapy. The reason for 
the difference in the cost of the third line is that more patients in 
cohort B progress from the second line to the third line therapy 
earlier than in cohort A. Yet the same transition probability is 
applied to both cohorts when progressing from third-line to 
fourth-line therapy. In other words, patients stay longer on third-
line therapy in cohort B than do those in cohort A. Net cost per 
patient is a little higher in cohort A than cohort B. The two cohorts 
have comparable but distinct net costs per patient ($21,732 vs 
$20,838) and the mean OS (34.92 months vs 33.97 months). 
The treatment sequence including PLD/carboplatin gained 0.041 
QALYs per patient and incurred $894 on average more than the 
treatment sequence including paclitaxel/carboplatin. Overall, 
the resulting incremental cost effectiveness ratio (ICER) was 
$21,658 per QALY and $67,761 per LYG.
One-way sensitivity analysis
To investigate the uncertainty, key parameters were varied in 
a one-way sensitivity analysis, and results are summarized in 
Table 6. Appropriate ranges of variation in parameters were 
determined based on clinical and economical perspectives. 
Two variables (ie, administration cost of PLD and clinical 
parameters of second-line therapies) had the biggest impact 
on the result. Except for these two parameters, ICERs were 
in the range of ￦16,781,475 ($14,851) to ￦32,166,198 
($28,466), which is within the acceptable range considering 
GDP per capita in Korea.
Variation in price of PLD
There is some uncertainty surrounding the price of PLD, 
because PLD has not yet been listed for reimbursement 
in Korea. In the base-case analysis, the price for a 50 mg 
(25 mL) pack of PLD is assumed to be ￦890,603 ($788), 
which is the price suggested by the manufacturer. When the 
price of PLD was varied within the range of ±5%, ICER 
changed between ￦16,781,475 ($14,851) and ￦32,166,198 
($28,466).
Variation in PLD administration cost
As mentioned before, PLD/carboplatin in the second line and 
carboplatin in the sixth line are supposed to be administered 
at 4-week intervals, according to the indication approved by 
the Korea Food and Drug Administration, while all the other 
chemotherapies are administered at 3-week intervals. However, 
the model cannot reflect this difference in administration 
interval. To fit our model specification, PLD/carboplatin and 
carboplatin were assumed to be given at 3-week intervals 
in the base-case analysis. Because carboplatin is included 
commonly in both treatment sequences, assumption of 3-week 
intervals of carboplatin turned out not to significantly impact 
the final ICER. However, PLD/carboplatin could cause some 
difference in the final result because it is a key subject of 
interest in this analysis.
The assumption of administration interval of PLD/
carboplatin of 3 weeks is a very conservative one, in 
that PLD cost is likely to be overestimated. In order to 
adjust the potential cost overestimation, PLD/carboplatin 
administration costs was varied to 3/4 and 7/8 of the cost of 
4-week intervals of PLD/carboplatin, respectively, for ICER 
calculation. One-way sensitivity analysis, based on these 
cost variations, now showed ICER estimates less than zero 
in both cases, which means that PLD/carboplatin dominates 
paclitaxel/carboplatin.
Table 4 Utility values for different health states
Health state TTO TTO 
(mean)
VAS VAS 
(mean)
Ovarian cancer: clinical remission 0.83 0.83 0.72 0.72
Recurrent ovarian cancer: 
responding to chemotherapy/ 
grade 1–2 toxicity
0.5 0.56 0.44 0.42
Recurrent ovarian cancer: 
responding to chemotherapy/ 
grade 3–4 toxicity
0.61 0.4
Recurrent ovarian cancer: 
progressive/grade 1–2 toxicity
0.4 0.435 0.36 0.315
Recurrent ovarian cancer: 
progressive/grade 3–4 toxicity
0.47 0.27
End-stage ovarian cancer 0.16 0.16 0.16 0.16
Abbreviations: TTO, time trade-off; VAS, visual analog scale.
Cohort A
PLD/carboplatin = 1,000
Topotecan = 616.54
Docetaxel = 386.13
Etoposide = 242.25
Carboplatin or cisplatin = 142.10
BSC = 48.54
Cohort B
Paclitaxel/carboplatin = 1,000
Topotecan = 699.26
Docetaxel = 438.32
Etoposide = 275.33
Carboplatin or cisplatin = 162.01
BSC = 55.98
Figure 2 Number of patients starting each line of therapy.
Abbreviations: PLD, polyethylene glycolated liposomal doxorubicin; BSC, best 
supportive care.
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Table 5 Result of base-case analysis
Line Cohort A, US$ (Korean won) Cohort B, US$ (Korean won) Difference
2nd 8,243,645 (9,315,318,744) 5,948,851 (6,722,201,396) 2,294,794 (2,593,117,348)
3rd 7,623,297 (8,614,325,333) 8,640,799 (9,764,102,974) −1,017,502 (−1,149,777,642)
4th 2,617,252 (2,957,494,436) 2,995,857 (3,385,206,829) −378,507 (−427,712,393)
5th 452,732 (511,587,701) 460,259 (520,092,811) −7,527 (–8,505,110)
6th 385,854 (436,015,528) 437,552 (494,434,201) −51,698 (–58,418,673)
BSC 654,985 (740,132,580) 743,578 (840,243,590) −88,594 (–100,111,009)
Net cost per patient 21,732 (24,557,344) 20,838 (23,547,138) 894 (1,010,206)
Mean survival (months) 34.92 33.97 0.95
LYs per patient 2.603 2.590 0.013
QALYs per patient 1.864 1.823 0.041
Cost per LY 8325 (9,406,876) 8026 (9,069,346) 299 (337,530)
Cost per QALY 11,626 (13,137,763) 11,402 (12,884,545) 224 (253,218)
incremental cost per QALY gained 21,658 (24,473,836)
incremental cost per LY gained 67,761 (76,569,719)
Abbreviations: BSC, best supportive care; QALYs, quality-adjusted life years; LY, life year.
Table 6 Result of one-way sensitivity analysis
Parameter varied Value in base case Variation of value Result, US$ 
(Korean won)
Price of PLD, US$ (Korean won) 788.15 (890,604) 5% reduction: 748.74 (846,073) 14,851 (16,781,475)
5% increase: 827.55 (935,133) 28,466 (32,166,198)
Discount rate Costs 5% 
Benefit 5%
Costs 0% and benefits 0% 17,131 (19,357,641)
Costs 3% and benefits 3% 19,754 (22,321,891)
Costs 7.5% and benefits 7.5% 24,207 (27,354,258)
Administration cost of PLD/carboplatin 
per administration cycle
4-week cost 3/4 of 4-week cost −31,515 (−35,611,603)
7/8 of 4-week cost −4,928 (−5,568,897)
Median TTP of BSC 4.5 months 3 months 21,984 (24,841,745)
6 months 21,337 (24,111,272)
Clinical parameter of 2nd-line therapy Parameters from CALYPSO 
study
Weighted average of median 
TTP drawn from all literature chosen
47,199 (53,335,223)
Utility TTO VAS 21,836 (24,674,656)
Sequence Topotecan → docetaxel → 
etoposide → (carboplatin or 
cisplatin)
Docetaxel → topotecan → 
etoposide → (cisplatin or carboplatin)
19,254 (21,757,519)
Docetaxel → topotecan → (cisplatin or 
carboplatin) → etoposide
20,602 (23,280,195)
Proportion of grade 1/2:3/4 of adverse 
events
50%:50% 40%:60% 22,087 (24,958,164)
70%:30% 20,849 (23,559,466)
Time horizon 10 years 15.5 years (time point at which all 
cohorts die)
20,937 (23,658,389)
Proportion of nonreimbursement cost Proportion of nonreimbursement 
cost of ambulatory services in all 
types of cancers: 15%
Proportion of nonreimbursement 
cost of all services in all types of cancers: 
26.70%
25,115 (28,380,301)
Assumed that there is no 
reimbursement: 0%
18,410 (20,862,761)
Abbreviations: PLD, polyethylene glycolated liposomal doxorubicin; TTP, time to progression; BSC, best supportive care; TTO, time trade-off; VAS, visual analog scale.
Variation in clinical parameter 
of second-line therapies
There is only one RCT that directly compared PLD/carboplatin 
with paclitaxel/carboplatin as second-line therapy for platinum-
sensitive recurrent ovarian cancer, and the results of this head-
to-head RCT were used in the base-case analysis.11
In a sensitivity analysis, the weighted average of data 
from all relevant literature comparing PLD/carboplatin or 
paclitaxel/carboplatin with other comparators was put into 
the model instead of the result of the head-to-head RCT. As 
a result, ICER increased to ￦53,335,223 ($47,199), which 
is about twice the base-case result.
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Variation in proportion of nonreimbursement cost
In the base-case analysis, the average proportion of the costs 
not reimbursed by insurance among ambulatory care costs 
in treatment of all types of cancers was applied, which was 
drawn from the report by the NHIC, since there were no 
ovarian cancer-specific data available.
When the nonreimbursement proportion of overall ser-
vices (ie, ambulatory care and hospitalization) was applied 
in the sensitivity analysis, ICER increased to ￦28,380,301 
($25,115). In addition, when it was assumed that all cost items 
were covered by insurance, ICER decreased to ￦20,862,761 
($18,410).
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA), involving 1000 
random simulations of median TTPs of each chemotherapy, 
cost of hospice service, and utilities according to each health 
state, was performed in order to quantify the uncertainty 
surrounding the parameters used in the model.
PSA is a technique for testing the robustness of the 
result by investigating how cost-effectiveness changes when 
multiple parameters are varied simultaneously. The 1000 
results from the PSA were plotted onto a cost-effectiveness 
plane (Figure 3). Most of the results of the 1000 simulations 
lie on the first quadrant, which means that PLD/carboplatin 
increases both QALYs and costs more than paclitaxel/
carboplatin.
Figure 4 shows the cost-effectiveness acceptability 
curve, presenting the probability that the treatment sequence 
including PLD/carboplatin is cost-effective compared with 
the alternative sequence for a range of maximum monetary 
values that a decision-maker might be willing to pay for 
1 QALY gained. We can see that PLD/carboplatin is cost-
effective in nearly 49.4% of samples at a willingness to pay 
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Figure 3 Cost-effectiveness plane.
Abbreviation: QALY, quality-adjusted life year.
30,00025,00020,00015,00010,0005,000-
0.600
0.500
0.400
0.300
0.200
0.100
0.000
P
ro
b
ab
ili
ty
Threshold
Figure 4 Cost-effectiveness acceptability curve.
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a threshold of $20,000, which is close to the GDP per capita 
of Korea.
Discussion
The CALYPSO study comparing PLD/carboplatin directly 
with paclitaxel/carboplatin as second-line therapy in 
platinum-sensitive recurrent ovarian cancer patients showed 
superiority in PFS and a better therapeutic index of PLD/
carboplatin over a standard paclitaxel/carboplatin regimen.1 
However, value for money of PLD/carboplatin in platinum-
sensitive patients has not yet been proven.
The main objective of this analysis was to estimate the 
long-term clinical impact and cost-effectiveness of PLD/
carboplatin in platinum-sensitive recurrent ovarian cancer in 
Korea. Efficacy such as PFS or OS might be important factors 
for decisions concerning drug selection for cancer patients in 
the clinical setting. However, straight comparison of efficacy 
outcomes can be misleading, because quality of life can be 
more valuable to cancer patients than mere extension of life. 
Some drugs have low tolerance, low compliance, or more 
adverse effects while prolonging PFS or OS, but efficacy 
measures can’t capture these aspects. Utility can combine 
this efficacy and quality of life into a single measure.26 
Accordingly, a cost–utility analysis was applied in this 
analysis to this end.
Analysis was performed through decision-modeling 
because the treatment sequences after second-line therapies 
in the trial were not presented clearly and were different 
between the two arms. The treatment-sequence model of 
ovarian cancer patients, including PLD/carboplatin and 
paclitaxel/carboplatin as a second line, was constructed 
to reflect clinical protocol for patients receiving series of 
chemotherapies, depending on responsiveness to drugs.
PLD is a kind of improved formulation of conventional 
doxorubicin and surrounded by fatty coating called liposome, 
which enables doxorubicin to remain longer inside the body. 
This means that more of the doxorubicin can be delivered 
to the target cancer cell, while having fewer side effects 
on healthy tissue. In fact, PLD/carboplatin can be used for 
metastatic breast cancer, Kaposi’s sarcoma, and ovarian 
cancer.27
The average median OS estimated by the model was 29.15 
and 29.26 months in the PLD/carboplatin and paclitaxel/
carboplatin arms, respectively. There was about a 3-month 
gap between OS of paclitaxel/carboplatin in the RCT and the 
one estimated by modeling, while OS of PLD/carboplatin 
in the RCT was similar to the one estimated by modeling. 
The reason for this is that OS in the RCT was not entirely due 
to the effect of PLD/carboplatin and paclitaxel/carboplatin, 
because the types of treatments after second-line therapy in 
the RCT were not controlled identically in both arms.
Predicted ICER under the base-case assumption was 
￦24,473,836 ($21,658) per QALY. It was not considered 
that there was a need to perform additional subgroup analysis, 
because the target of the base-case analysis, ie, platinum-
sensitive recurrent ovarian cancer patients, was already 
narrowed down. One-way sensitivity analysis showed that 
when key parameters were varied, ICERs (QALYs) lay in the 
range of ￦16,781,475 ($14,851) to ￦32,166,198 ($28,466), 
except when administration cost of PLD/carboplatin and 
source of clinical parameters of second-line therapies were 
varied. Probability sensitivity analysis revealed that there 
is sufficient uncertainty surrounding the baseline ICER. 
The cost-effectiveness acceptability curve demonstrated 
that there is about 49.4% probability of cost-effectiveness 
in the treatment sequence including PLD/carboplatin when 
decision-makers have the willingness to pay the threshold of 
$20,000, which was the GDP per capita of Korea in 2010.
When considering clinical superiority, cost-effectiveness 
of PLD, and current limited therapeutic options in platinum-
sensitive recurrent ovarian cancer, overall, PLD/carboplatin can 
be said to be a valuable treatment option in these patients.
Although this economic analysis was performed according 
to the current methodological guidelines recommended, 
there are a few caveats. Firstly, although the administration 
cycle of PLD/carboplatin and carboplatin is 4 weeks, it 
was assumed to be 3 weeks because other chemotherapies, 
except for PLD/carboplatin and carboplatin, are administered 
every 3 weeks, and the model cannot reflect this difference 
in the administration interval. ICER was very sensitive to 
the variation of administration cost of PLD/carboplatin. 
However, we can guess that this is a conservative assumption 
for PLD/carboplatin, because the cost of PLD/carboplatin 
was put into the model more frequently than it should have 
been under this assumption. PLD/carboplatin would become 
even more cost-effective if the administration cycle of PLD/
carboplatin could be reflected precisely.
Secondly, indirect costs incurred by patients and informal 
caregivers, such as cost of productivity loss, were not 
included. Incorporation of these societal costs would further 
decrease ICER to an even lower level.
Finally, we used OS data of the CALYPSO study, 
reported in proceedings because it has not been 
published yet. In addition, chemotherapies administered 
after PLD/carboplatin and paclitaxel/carboplatin until death 
were not controlled identically between the two groups in the 
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trial, because it was not OS but median TTP which was the 
main key outcome. Therefore, it cannot be said that the OS 
result was entirely due to the effect of PLD/carboplatin and 
paclitaxel/carboplatin. Nevertheless, OS in the CALYPSO 
study was used, because there were no other data that were 
more reliable.
In conclusion, PLD/carboplatin as a second therapeutic 
option in patients with platinum-sensitive recurrent ovarian 
cancer is cost-effective compared to the standard paclitaxel/
carboplatin regimen, based on clinical and economical 
perspectives. These data can provide an objective basis for 
local decision-making on the possible economic impact of 
use of this intervention if different variables between the 
countries can be incorporated accordingly.
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